1-5 of 5
K. Sue Robinson, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ten Percent of Newly Diagnosed CLL Patients Are Treated within the First Year of Diagnosis: Results of a Canadian Retrospective Population-Based Study

Natasha Pardy, MD, David Conrad, MDPhD, Steve Doucette, MSc, K. Sue Robinson, MD, Stephen Couban, MD, Sudeep Shivakumar, MD
Journal: Blood
Blood (2015) 126 (23): 5282.
https://doi.org/10.1182/blood.V126.23.5282.5282
Published: 2015
Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Kirsten Fischer, MD, Anna-Maria Fink, MD, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y. Choi, MD, Robert Weinkove, MD PhD, K. Sue Robinson, MD, Martin Dreyling, MD PhD, Till Seiler, MD, Stephen Opat, MD, Carolyn Owen, MD, Javier Lopez, Sr., MD PhD, Nadine Kutsch, MD, Eugen Tausch, MD, Matthias Ritgen, MD, Rod A. Humerickhouse, MD PhD, Kathryn Humphrey, Michael K. Wenger, MD, Valentin Goede, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Thomas J. Kipps, MD PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 496.
https://doi.org/10.1182/blood.V126.23.496.496
Published: 2015
Journal Articles

Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.

Brad Kahl, MD, Nancy L. Bartlett, MD, John P. Leonard, MD, Kristen Ganjoo, MD, Michael E. Williams, MD, Myron S. Czuczman, MD, K. Sue Robinson, MD, Robin Joyce, MD, Richard H. van der Jagt, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2007) 110 (11): 1351.
https://doi.org/10.1182/blood.V110.11.1351.1351
Published: 2007
Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

Jonathan W. Friedberg, MD, Philip Cohen, MD, Bruce D. Cheson, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Luis Fayad, MD, Ann S. La Casce, MD, Alberto Bessudo, MD, Elber S. Camacho, MD, Michael E. Williams, MD, Richard H. van der Jagt, MD, Jennifer Oliver, MD, Ely Benaim, MD
Journal: Blood
Blood (2005) 106 (11): 229.
https://doi.org/10.1182/blood.V106.11.229.229
Published: 2005
Journal Articles

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Jonathan Friedberg, MD, Philip Cohen, MD, Robert O. Kerr, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Richard van der Jagt, MD, Elber Camacho, MD, John Hainsworth, MD, Brent Roeck, Pratik S. Multani, MD
Journal: Blood
Blood (2004) 104 (11): 2480.
https://doi.org/10.1182/blood.V104.11.2480.2480
Published: 2004